3i Group plc has partnered with Hanns-Christian Mahler to create Ten23 Health, a drug product contract development and manufacturing organization focused on helping innovative biotech and pharma customers develop and commercialize injectable biopharmaceutical drugs.
Headquartered in Basel, Switzerland, ten23 health’s core service offering includes formulation development, drug product development and manufacturing, as well as testing services for sterile pharmaceutical products.
Richard Relyea, partner, 3i, commented, “We are delighted to be backing Hanns-Christian and the whole Ten23 Health team to build a leading biologics-focused CDMO. Hanns-Christian is one of the foremost leaders in a high-growth field who brings a proven track record in the biologics market. He has built a highly experienced team of experts and senior leaders with excellent credentials in the field of pharmaceutical product design and development and with an extensive global pharma network. We look forward to supporting Ten23 Health’s outstanding leadership team in growing the company and expanding its capabilities globally.”
Mahler, CEO, Ten23 Health, added, “There is significant unmet need in the biotech market as the number and complexity of molecules and therapeutic modalities increase which brings growing challenges with respect to stability, usability, and the successful commercialization of medicines. Our comprehensive offering will allow our clients to focus on the medicine and the patient, whilst leveraging our pharmaceutical expertise and knowledge to plan and de-risk product development. As a result, our strategic partners will profit from shorter product timelines and higher probability of
technical success, ultimately leading to improved paths to commercialization and maximized return on R&D efforts. I’m delighted to be partnering with Richard and the team at 3i to create a leading biologics CDMO that can meet the evolving needs of our customers with expert service, a true partnership model with our clients, and a patient-centric focus.”